Taking inhalable medicine further with the smallest, simplest, most affordable single-dose dry-powder inhaler

So much more than respiratory

We rely on inhalable medicines to treat conditions like asthma, epilepsy, allergies and Parkinson’s. But delivery devices remain clunky, costly and tough on the environment.

Vaccines, anti-infectives and rapid pandemic response would all benefit from easy, painless, self-administered delivery too. Meanwhile, bulky plastic capsule inhalers are the only option available for clinical trials.

What these all need is a small, easy-to-use, cost-effective, low carbon impact device to deliver these medicines.

The 1nhaler is that device.

Convenience baked in

Designed by an inhaler user, for inhaler users, the 1nhaler is uniquely portable, discreet and incredibly simple to use.

Simpler to use

Cheaper to make

Easier to distribute

And small enough to slip into your wallet - ready where and when you need it!

Super-compact and lightweight: easy to store and distribute
Simple to use: just click and breathe
Economical to produce: one process, five components
Low carbon footprint: propellant-free, predominantly cardboard, minimal API wastage
Affordable: Target COG 10P/C
Novel and ‘cool’: users love it!

It’s all about performance

There is no better drug to demonstrate the potential of the 1nhaler platform than the benchmark salbutamol API.

That's why salbutamol for asthma relief is our lead project and technical proof of concept

We are proud to report that the data for our lead project, salbutamol for asthma rescue, is comparable with the market-leading inhaler for drug deposition to the lungs.

It’s all about performance

There is no better drug to demonstrate the potential of the 1nhaler dry powder drug delivery platform than the benchmark salbutamol API.

That's why salbutamol for asthma relief is our lead project and technical proof of concept.

We are proud to report that the data for our lead project, salbutamol for asthma rescue, is comparable with the market-leading inhaler for drug deposition to the lungs.

[Additional info here ]

We are on track to transfer our lead project into CDMO later this year and conduct early clinical trials at the start of 2026.

CRO

Anything further?